Analysts forecast that Cardlytics Inc (NASDAQ:CDLX) will report sales of $36.00 million for the current quarter, according to Zacks. Five analysts have provided estimates for Cardlytics’ earnings, with estimates ranging from $35.40 million to $36.37 million. Cardlytics posted sales of $32.71 million during the same quarter last year, which would indicate a positive year-over-year growth rate of 10.1%. The business is scheduled to issue its next earnings results on Thursday, May 9th.

According to Zacks, analysts expect that Cardlytics will report full-year sales of $186.68 million for the current fiscal year, with estimates ranging from $178.70 million to $192.98 million. For the next financial year, analysts expect that the business will report sales of $264.90 million, with estimates ranging from $238.40 million to $284.80 million. Zacks’ sales calculations are an average based on a survey of sell-side analysts that that provide coverage for Cardlytics.

Cardlytics (NASDAQ:CDLX) last released its quarterly earnings data on Tuesday, March 5th. The company reported ($0.51) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.40) by ($0.11). Cardlytics had a negative net margin of 35.20% and a negative return on equity of 92.07%. The firm had revenue of $47.82 million for the quarter, compared to analyst estimates of $45.32 million.

A number of analysts have weighed in on CDLX shares. Zacks Investment Research raised Cardlytics from a “hold” rating to a “buy” rating and set a $21.00 price target for the company in a research report on Wednesday, March 6th. SunTrust Banks reaffirmed a “buy” rating and issued a $25.00 price target on shares of Cardlytics in a research report on Wednesday, March 6th. Finally, Bank of America raised Cardlytics from a “neutral” rating to a “buy” rating and set a $15.00 price target for the company in a research report on Tuesday, January 15th. One research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. Cardlytics has an average rating of “Buy” and an average target price of $22.86.

Shares of NASDAQ:CDLX opened at $14.75 on Friday. Cardlytics has a fifty-two week low of $9.80 and a fifty-two week high of $28.29. The stock has a market capitalization of $298.89 million, a price-to-earnings ratio of -6.89 and a beta of 3.62. The company has a quick ratio of 2.40, a current ratio of 2.40 and a debt-to-equity ratio of 0.90.

In other news, CFO David Thomas Evans sold 2,505 shares of Cardlytics stock in a transaction dated Friday, March 29th. The stock was sold at an average price of $16.21, for a total value of $40,606.05. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Kirk Somers sold 2,591 shares of Cardlytics stock in a transaction dated Thursday, March 21st. The stock was sold at an average price of $15.67, for a total value of $40,600.97. The disclosure for this sale can be found here. Insiders sold 22,087 shares of company stock worth $348,050 over the last quarter.

Several institutional investors have recently bought and sold shares of the company. FMR LLC increased its stake in shares of Cardlytics by 0.5% in the fourth quarter. FMR LLC now owns 3,211,725 shares of the company’s stock worth $34,783,000 after purchasing an additional 17,153 shares during the period. Canaan Partners VIII LLC bought a new position in shares of Cardlytics in the fourth quarter worth about $25,647,000. Frontier Capital Management Co. LLC increased its stake in shares of Cardlytics by 105.6% in the fourth quarter. Frontier Capital Management Co. LLC now owns 1,462,777 shares of the company’s stock worth $15,842,000 after purchasing an additional 751,148 shares during the period. Jennison Associates LLC increased its stake in shares of Cardlytics by 58.3% in the fourth quarter. Jennison Associates LLC now owns 1,264,354 shares of the company’s stock worth $13,693,000 after purchasing an additional 465,855 shares during the period. Finally, Cannell Capital LLC bought a new position in shares of Cardlytics in the fourth quarter worth about $5,491,000. Institutional investors and hedge funds own 80.89% of the company’s stock.

Cardlytics Company Profile

Cardlytics, Inc operates a purchase intelligence platform in the United States and the United Kingdom. It operates in two segments, Cardlytics Direct and Other Platform Solutions. The company's platform is the Cardlytics Direct solution, a proprietary native bank advertising channel that enables marketers to reach consumers through their trusted and frequently visited online and mobile banking channels.

Featured Article: How to Trade Using Analysts Ratings

Get a free copy of the Zacks research report on Cardlytics (CDLX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Cardlytics (NASDAQ:CDLX)

Receive News & Ratings for Cardlytics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardlytics and related companies with MarketBeat.com's FREE daily email newsletter.